Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q3 Loss
Portfolio Pulse from
Cyclacel Pharmaceuticals, Inc. (CYCC) reported a Q3 loss of $0.18 per share, which was better than the Zacks Consensus Estimate of a $0.54 loss. This is a significant improvement from the $7.35 loss per share a year ago.
November 13, 2024 | 12:15 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cyclacel Pharmaceuticals reported a Q3 loss of $0.18 per share, better than expected and a significant improvement from last year's $7.35 loss per share.
The reported loss per share of $0.18 is significantly better than the expected loss of $0.54 and shows a major improvement from the previous year's loss of $7.35 per share. This positive earnings surprise is likely to have a favorable impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100